Strong growth anchored in Obesity and GLP-1 momentum despite R&D headwinds for Novo Nordisk in Q2 2025
Overview Novo Nordisk delivered a solid Q2 2025, supported by expanding demand for its GLP-1-based diabetes treatments and strong uptake of obesity care therapies. The company maintained robust profitability, while continuing to invest in R&D and manufacturing expansion. Management reiterated its strategic focus on innovation, supply resilience, and long-term value creation. Lars Fruergaard Jørgensen, president…
